Drugs / MK-5108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00543387 | Mar 2008 → Apr 2011 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-5108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00543387 ↗ |
| Known as | VX-689 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3600873 ↗ |
| Action | Inhibit | “MK-5108 is a potent/highly selective Aurora A kinase inhibitor.” PMID 26620496 ↗ Dec 2015 |
| Modality | Small molecule | — CHEMBL3600873 ↗ |
| Route | Oral | “MK-5108 will be administered orally” NCT00543387 ↗ |
| Target | AURKA | “MK-5108 is a potent/highly selective Aurora A kinase inhibitor.” PMID 26620496 ↗ Dec 2015 |